Pathological Complete Response in a Patient With HER2-Negative Esophagogastric Junction Cancer Undergoing Conversion-Intent Surgery After Ramucirumab Plus Paclitaxel Following Nivolumab-Based Chemotherapy: A Case Report

Pathological Complete Response and Conversion Gastrectomy after Nivolumab Plus FOLFOX in an 84-Year-Old Man with MSI-High Gastric Cancer Presenting as a Sister Mary Joseph Nodule: A Case Report.

A Sister Mary Joseph nodule is a cutaneous umbilical metastasis indicating advanced intra-abdominal malignancy with a poor prognosis. An 84-year-old man presented with an umbilical nodule that was completely excised and diagnosed to be metastatic adenocarcinoma from advanced gastric cancer. After FOLFOX-nivolumab, the...

Successful Conversion Surgery after S-1 plus oxaliplatin Plus Zolbetuximab for Initially Unresectable Gastric Cancer with Pancreatic Invasion: A Case Report

ABSTRACT INTRODUCTION Zolbetuximab, a monoclonal antibody targeting claudin 18.2 (CLDN18.2), has recently demonstrated significant survival benefits when combined with chemotherapy for advanced gastric cancer. However, evidence regarding conversion surgery following SOX plus zolbetuximab therapy remains extremely limit...

Complete pathological response after neoadjuvant chemoimmunotherapy in PD-L1-negative unresectable primary hepatic small cell carcinoma: a case report and tumor microenvironment analysis

Background Primary hepatic small cell carcinoma (PHSCC) is an extraordinarily rare and aggressive malignancy with a dismal prognosis. No standard treatment exists, and the role of immunotherapy in this tumor type, especially in programmed cell death ligand 1 (PD-L1) negative cases, remains unexplored. Case presentation...

Pembrolizumab plus chemotherapy as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: 4.5-year follow-up from the randomized phase III KEYNOTE-859 study

Background KEYNOTE-859 showed a favorable benefit–risk profile for pembrolizumab plus chemotherapy compared with placebo plus chemotherapy, regardless of programmed death-ligand 1 (PD-L1) status, in participants with untreated locally advanced or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastr...

P1.127. A Case of Unresectable Advanced Esophageal Cancer Successfully Treated With ICI Regimen and RIC

Esophageal Cancer: Oncology/Radiation Therapy Immune checkpoint inhibitors are used for unresectable, advanced, and recurrent esophageal cancer. Currently, the Japan Esophageal Society recommends a 5Fu/CDDP + ICI regimen as first-line treatment. Here, we present a suggestive case of a patient with dysphasi...

Perioperative Outcomes and Pathological Response After Neoadjuvant Nivolumab Plus Platinum Chemotherapy in Clinically Node-Negative Non-Small Cell Lung Cancer.